Barclays keeps EUR 260.00 target for UCB stock, 26.64 percent above price

Published on 10/15/2026 at 15:11 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half revenue reached EUR 4.27 billion, up 23.00 percent. UCB stock costs EUR 205.35 on October 15, 2026, 1.66 percent above Xetra close.

Target and operating figures

Barclays maintained its Hold rating and EUR 260.00 target for UCB on October 2, 2026.
UCB reported first-half 2026 revenue of EUR 4.27 billion, up 23.00 percent year over year.
UCB stock costs EUR 205.35 at Lang & Schwarz on October 15, 2026 at 3:02 p.m. CEST, 1.66 percent above the Xetra close of October 14, 2026.
UCB trades at a P/E ratio of 17.80 and has a market capitalization of EUR 39.3 billion.

Schwarzweiß-Reportagefoto einer Wissenschaftlerin bei der Untersuchung einer Petrischale im Labor — UCB S.A. (BE0003739530) dokumentarisch: authentische Schwarzweiß-Reportage einer Wissenschaftlerin bei sorgfältiger Laboranalyse mit Petrischale, Illustration mit AI erstellt.

Barclays maintained its Hold rating and a EUR 260.00 price target for UCB on October 2, 2026, according to Markets Insider. The target is 26.64 percent above the EUR 205.35 price at Lang & Schwarz. UCB stock was trading 1.66 percent above the Xetra close of October 14, 2026 at EUR 202.00.

Revenue gives the target context

UCB reported first-half 2026 revenue of EUR 4.27 billion, up 23.00 percent from EUR 3.49 billion in the comparable period, while net profit reached EUR 1.11 billion against EUR 475 million a year earlier, according to Markets Insider. The figures place product growth at the center of the current valuation discussion.

UCB stock stays above its yearly low

UCB stock traded between EUR 197.45 and EUR 203.10 on October 14, 2026, and its 52-week range was EUR 197.45 to EUR 289.50. The Lang & Schwarz price of EUR 205.35 on October 15, 2026 at 3:02 p.m. CEST stands 4.00 percent above the 52-week low and 29.03 percent below the high. The company has a market capitalization of EUR 39.3 billion and a P/E ratio of 17.80.

Valuation versus large drugmakers

UCB's valuation is lower than the P/E ratio of 22.92 for Novartis, whose market capitalization was CHF 236.8 billion and whose stock was up 1.58 percent on October 15, 2026. Roche traded at a P/E ratio of 20.09 with a market capitalization of CHF 256.6 billion and a 0.50 percent gain as of March 16, 2026.

Comparison with peers

UCB: plus 1.66 percent, P/E 17.80, market capitalization EUR 39.3 billion
Novartis (SIX, CHF): plus 1.58 percent, P/E 22.92, market capitalization CHF 236.8 billion
Roche (SIX, CHF): plus 0.50 percent, P/E 20.09, market capitalization CHF 256.6 billion

What the target means for UCB stock

Barclays' EUR 260.00 target leaves a 26.64 percent gap above the Lang & Schwarz price. The comparison with larger Swiss drugmakers gives the valuation figure a clear market reference, while UCB's first-half revenue growth provides the operating counterweight.

Price and valuation remain central

UCB stock was trading at EUR 205.35 at Lang & Schwarz on October 15, 2026 at 3:02 p.m. CEST, up 1.66 percent versus the Xetra close of October 14, 2026 at EUR 202.00. The further course of trading is shown by the continuously updated real-time quote of UCB stock.